2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Glioblastoma
49
Brain Neoplasms
25
Central Nervous System Neoplasms
22
Astrocytoma
17
Glioma
15
Medulloblastoma
11
Neoplasms
8
Oligodendroglioma
7
Lymphoma
7
Recurrence
6
Gliosarcoma
6
Spinal Cord Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, AIDS-Related
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Ependymoma
2
Burkitt Lymphoma
2
Uveal Melanoma
1
Solid Tumor
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Optic Nerve Glioma
1
Newly Diagnosed High Grade Glioma
1
Neuroectodermal Tumors, Primitive
1
Neuroectodermal Tumors
1
Interventions
Rituximab
17
Peripheral Blood Stem Cell Transplantation
15
Cyclophosphamide
15
fludarabine phosphate
12
Whole-Body Irradiation
11
Cyclosporine
10
Mycophenolic Acid
9
Etoposide
9
Methotrexate
8
Filgrastim
8
Lenalidomide
7
Tacrolimus
6
Dexamethasone
6
Busulfan
6
Radiotherapy
5
Melphalan
5
Cytarabine
5
Carboplatin
5
Vorinostat
4
Thiotepa
4
Therapeutics
4
Psychiatric Rehabilitation
4
Bortezomib
4
Antilymphocyte Serum
4
Transplantation
3
Methylprednisolone
3
Irinotecan
3
Granulocyte Colony-Stimulating Factor
3
Flow Cytometry
3
Dasatinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Intraocular Lymphoma
×
Lomustine
×
Clear all
NCT00074191
2017-04-21
Protocol-A
OHSU Knight Cancer Institute
Phase 2
Completed
1 enrolled